Santé log

ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories

ProPhase Labs, Inc. (NASDAQ: PRPH) ("ProPhase") and Advanced Biological Laboratories S.A. ("ABL"), a European biotechnology and MedTech group, today announced that they have entered into a non-binding ...
Santé log

OKYO Pharma to Ring the Opening Bell at Nasdaq

The Opening Bell ceremony will be broadcast live at 9:30 a.m. ET and live streamed to Nasdaq's official channels. To view the live broadcast, visit: ...
Santé log

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Participants receiving pemvidutide 1.2 mg and 1.8 mg achieved weight loss of 4.5% and 7.5%, respectively, vs. 0.2% of placebo-treated participants (p<0.0001, both doses), with no plateauing at 48 ...
Santé log

Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial

Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today ...
Santé log

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

Earlier this year MSD exercised its option on a separate Evaxion vaccine candidate, EVX-B3. Evaxion is eligible for milestone payments up to $592 million associated with the development of EVX-B3, as ...
Santé log

The Ensign Group, Inc. Increases Quarterly Dividend to $0.0650 Per Share

Ensign has been a dividend-paying company since 2002.
Santé log

GUERBET: Nomination de M. François Convenant en tant que Senior Vice-Président Radiologie Interventionnelle et son entrée au Comité Exécutif

GUERBET (FR0000032526 GBT), acteur mondial de l’imagerie médicale, annonce la nomination de François Convenant au poste de Senior Vice-Président Radiologie Interventionnelle. À ce titre, il rejoint le ...
Santé log

DXS INTERNATIONAL PLC (AQSE: DXSP) Result of AGM

The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce that ...
Santé log

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living ...
Santé log

Ipsen fait le point sur l'essai de Phase II FALKON chez les patients atteints d’une maladie osseuse ultra-rare, la fibrodysplasie ossifiante progressive (FOP)

PARIS, FRANCE – 19 décembre 2025 – Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd'hui que l'essai pivotal de Phase II FALKON n'a pas atteint son critère principal, à savoir la réduction du volum ...
Santé log

Genenta Science Provides Update on CEO Ownership

As calculated in accordance with SEC rules, as of December 19, 2025, Mr. Paracchi owns 2,326,129 ADSs and ordinary shares in the aggregate, representing approximately 10% of Genenta’s outstanding ...
Santé log

Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone

Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone ...